Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab vs Methotrexate for GVHD Prophylaxis in B-cell Neoplasms
NCT02701517Phase 2Terminated
- Sponsor
- GELTAMO
- Start
- Sep 2003
- Primary completion
- Nov 2009
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of alemtuzumab in chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by GELTAMO. Primary endpoint: Event-Free Survival. Started Sep 2003; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02701517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02701517.